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Abstract.12




Objective: The first aim of the study was to investigate prevalence and clinical characteristics of epilepsy in a large cohort
of patients with neurodegenerative dementias. Subsequently, we explored clinical, neuropsychological, and quantitative






Methods: We retrospectively evaluated consecutive patients with a diagnosis of a neurodegenerative dementia and a clinically
diagnosed epilepsy that required antiepileptic drugs (AED). All patients underwent baseline comprehensive neuropsycho-
logical assessment. A follow-up of at least one year was requested to confirm the dementia diagnosis. In AD patients, qEEG







Results: Thirty-eight out of 2,054 neurodegenerative dementia patients had epilepsy requiring AED. The prevalence of
epilepsy was 1.82% for AD, 1.28% for the behavioral variant of frontotemporal dementia (bvFTD), 2.47% for dementia
with Lewy bodies (DLB), and 12% for primary progressive aphasia. Epilepsy were more drug-responsive in AD than in







Conclusion: In our cohort, AD, FTD, and DLB dementias have similar prevalence of epilepsy, even if AD patients were
more responsive to AED. Moreover, AD-EPI patients did not have significant clinical, neuropsychological qEEG differences
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INTRODUCTION 33
Although it is known that demented patients are 34
more prone to present seizures than subjects with- 35
out dementia [1, 2], precise epidemiologic data 36
of epilepsy in dementia is lacking [1] and, on 37
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the other hand, it is known that old people with38
epilepsy are at increased risk of cognitive decline39
[3], as cognitive impairment across all domains40
has actually been reported in these patients [4].41
Overall, cognitive decline over time in people with42
epilepsy is faster compared to aging-related cognitive43
decline in subjects without epilepsy [5]. Further-44
more, a bidirectional relationship between epilepsy45
and dementia has been suggested [3]. Thus, the con-46
cept of an accelerated cognitive aging in patients47
with epilepsy has been suggested [5], but it is still48
unknown whether dementia worsens more rapidly49
in demented patients with epilepsy compared to50
those without.51
Gowers first introduced the concept of epileptic52
dementia, implying that in some subjects dementia53
and epilepsy may be the consequence of the same54
underlying disorder [6]. The association between55
vascular dementia and epilepsy is common [7].56
Neurodegenerative dementias as well may develop57
seizures. Alzheimer’s disease (AD) is the most fre-58
quent cause of dementia and is frequently associated59
with epilepsy [8], but non-AD dementia patients may60
also have epilepsy [9]. However, most of the pub-61
lished studies investigating the association between62
dementia and epilepsy did not evaluate the causes63
of dementia. Moreover, neurophysiological and neu-64
ropsychological features of dementia patients with65
dementia epilepsy are lacking.66
This study has two aims: 1) to investigate the preva-67
lence and the clinical characteristics of epilepsy in68
a large cohort of patients with neurodegenerative69
dementias; and 2) to explore clinical, neuropsycho-70
logical, and electroencephalogram (EEG) data of AD71




We retrospectively evaluated consecutive patients76
admitted to our University Hospital memory clinic77
between January 1999 and December 2016. The main78
inclusion criteria were 1) a diagnosis of neurodegen-79
erative dementia and 2) the presence of seizures under80
antiepileptic drug (AED) treatment with an onset81
close to the time of dementia diagnosis or later on82
during the follow-up.83
The patients underwent a baseline clinical assess-84
ment including neurological examination and neu-85
ropsychological evaluation. They underwent brain86
magnetic resonance imaging (MRI), or computed 87
tomography in the case MRI was unfeasible. They 88
also underwent ambulatory scalp EEG during relaxed 89
wakefulness. When the clinical diagnosis was uncer- 90
tain, patients underwent brain radionuclide imaging, 91
including brain perfusion 99mTc-ECD single photon 92
emission tomography (SPECT) or brain metabolism 93
18F-FDG positron emission tomography (PET). 94
The main exclusion criteria were 1) a remote his- 95
tory of epilepsy (defined as seizure onset at least 5 96
years prior to cognitive symptoms [2]) and 2) a history 97
of stroke and/or a diagnosis of vascular dementia [10], 98
including mixed neurodegenerative/vascular demen- 99
tia, with cortical/iuxtacortical infarcts. 100
The diagnosis of neurodegenerative dementia was 101
made according to the following criteria: 102
• AD: according to the 1984 NINCDS-ADRDA 103
Alzheimer’s Criteria [11] for patients diagnosed 104
between 1999 and 2011, and according to the 105
2011 NIA-AA criteria [12] for patients diag- 106
nosed from 2011. 107
• Frontotemporal dementia (FTD): according to 108
the 1998 criteria [13] for patients diagnosed from 109
1999 to 2011, after 2011 the criteria for behav- 110
ioral variant FTD (bvFTD) were used [14]. 111
• Dementia with Lewy bodies (DLB): according 112
to the 1996 criteria [15] for patients diagnosed 113
from 1999 to 2005, and according to the 2005 114
criteria of the international consortium on the 115
DLB [16] for patients from 2005. 116
• Parkinson’s disease dementia (PDD): according 117
to the Movement Disorder Society criteria [17]. 118
• Primary progressive aphasia (PPA): according 119
to the 1987 criteria [18] for patients diagnosed 120
from 1999 to 2011, and according to the 2011 121
criteria [19] for patients from 2011. 122
• Posterior cortical atrophy (PCA): according to 123
the criteria of Benson and collaborators of 1988 124
[20]. 125
The patients underwent six month-based clinical 126
follow-up after the baseline assessment. A follow- 127
up of at least one year was requested to confirm the 128
diagnosis. 129
For each patient, a case report form (CRF) was 130
created, including age, gender, years of education, 131
type of dementia diagnosis, the onset of seizures 132
(before, after or concomitant with the diagnosis of 133
dementia), and the type of seizure at onset (focal, 134
generalized or unknown), seizure type classification 135
basic version [24], AED treatment and the response to 136
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Patients were considered improved by therapy when138
an improvement in either frequency or intensity of139
seizures was judged clinically significant by the neu-140
rologist.141
The study protocol met the approval of the local142
Ethics Committee, and all participants signed an143
informed consent form in compliance with the144
Helsinki Declaration of 1975.145
Neuropsychological evaluation146
The following neuropsychological evaluation was147
performed at baseline: 1) categorical and phono-148
logical verbal fluency to asses language [21]; 2)149
Trail-Making Test (TMT) A [22], Stroop color-word150
test [23], and digit span [24] to evaluate attention and151
working memory; 3) TMT B [22], Stroop color test152
[23], and symbol-digit [25] for executive functions;153
4) Clock Drawing Test (CDT) [26] and figure copy-154
ing of the mental deterioration battery (simple copy155
and copy with guiding landmarks) [27] for visuospa-156
tial capabilities; and 5) Rey auditory learning verbal157
test [28] (RALVT, immediate and delayed recall) and158
Corsi’s block design [29] to investigate memory.159
The Mini-Mental State Examination (MMSE) [30]160
was performed as a general measure of cognitive161
functioning. The Geriatric Depression Scale (GDS)162
[31] was used to investigate the presence of depres-163
sion.164
EEG recording and data processing165
EEG recordings were obtained from patients166
seated in a recliner with eyes closed. EEG electrodes167
were placed using standard 10–20 EEG electrode168
positions: Fp2, F4, Fp1, F3, and Fpz (frontal); F8,169
T4, T6, F7, T3, and T5 (temporal); C4 P4, C3, P3,170
PZ, and CZ (centro-parietal); O2 and O1 (occipital).171
Recordings were referenced to the Fpz electrode, Oz172
electrode served as ground. EEG was recorded with173
a sampling rate of 256 Hz, at a bandpass filter of174
0.5–70 Hz.175
EEG data were manually analyzed off-line to176
reject artifacts. One minute of artifact-free EEG data177
was re-referenced to common average for further178
analysis. Quantitative EEG (qEEG) power spectrum179
was calculated with the Fourier Transform (Welch180
method), applied to 2-s segments with 2-s overlap181
(Tukey window), for each brain area (i.e., frontal,182
temporal, centro-parietal, and occipital). The EEG183
spectrum was then divided into the following fre-184
quency bands: delta (2.10–4 Hz), theta (4.10–8 Hz),185
alpha (8.10–12 Hz), sigma (12.10–16 Hz), and beta 186
(16.10–24 Hz) and relative power was computed for 187
each band as normalized to the total EEG power. In 188
order to evaluate EEG power distribution in a large 189
band (2–16 Hz), the power-weighted mean frequency 190
(MF) was calculated for each brain area. 191
Statistical analysis 192
The first analysis was aimed at evaluating the rela- 193
tionship between epilepsy and the different types 194
of neurodegenerative dementia. The prevalence of 195
epilepsy was calculated for each type of neurode- 196
generative dementia. Then, a logistic regression was 197
performed, using the diagnosis of neurodegenerative 198
dementia as the dependent variable (categorical vari- 199
able) and the characteristics of epilepsy included in 200
the CRF, as detailed before, were the independent 201
variables. 202
The second analysis was aimed at comparing clin- 203
ical features, neuropsychological tests scores and 204
qEEG data of subjects suffering from AD and 205
epilepsy (AD-EPI) with subjects suffering from AD, 206
without epilepsy (AD-CTR). The two groups were 207
matched for age, MMSE score, and gender. Contin- 208
uous variables were analyzed by unpaired t test and 209
categorical variables with the chi-square test. 210
RESULTS 211
Epilepsy and neurodegenerative dementias 212
From 1996 to 2016, we found in our clinical 213
database 2,054 patients with diagnosis of neurode- 214
generative dementia (Supplementary Figure 1). 1,645 215
were AD (80.09%), 235 bvFTD (11.44%), 81 DLB 216
(3.94%), 64 PDD (3.12%), 25 PPA (1.2%), and 4 217
PCA (0.19%). 218
Among these patients, 38 (1.85%) were affected by 219
epilepsy (Fig. 1). Among these, 30 were diagnosed 220
with AD (78.95%), 3 had bvFTD (7.89%), 3 PPA 221
(7.89%), and 2 DLB (5.26%). 222
Large epidemiology studies have shown that the 223
prevalence of epilepsy in the elderly ranged from 0.5 224
% [9] to 0.97 % [2]. In our cohort of neurodegenera- 225
tive dementias, prevalence of epilepsy is significantly 226
higher compared to literature data of epilepsy in the 227
elderly (p < 0.001, Fisher Exact Test). 228
In our cohort of neurodegenerative dementias, the 229
prevalence of epilepsy was 1.82% for AD, 1.28% for 230
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Fig. 1. Distribution of neurodegenerative dementias in the study
group of dementia patients with concomitant epilepsy. AD,
Alzheimer’s disease; DLB, dementia with Lewy Bodies; bvFTD,
fronto-temporal dementia, behavioral variant; PPA, primary pro-
gressive aphasia.
mentary Figure 2). The characteristics of epileptic232
seizures are shown in Table 1.233
Logistic regression showed a significant correla-234
tion (p < 0.0001) between dementia and treatment235
response. In particular, 23 patients with AD (76.7%)236
were seizure free after using AEDs.237
Epilepsy and Alzheimer’s disease238
Eight patients in the AD-EPI group had an EEG239
with insufficient quality to perform qEEG analysis,240
thus 22 AD-EPI patients were considered for subse-241
quent analysis. Main clinical and demographic data242
of AD patients with and without epilepsy are summa-243
rized in Table 2. Per selection criteria of AD patients244
without epilepsy that were chosen so as to be age and 245
severity-matched with those with epilepsy, no statis- 246
tically significant difference was found between the 247
two groups. 248
Neuropsychological tests score of AD patients 249
with and without epilepsy are shown in Table 3. 250
Considering that the two groups were matched for 251
age, gender, education, and MMSE, raw neuropsy- 252
chological data were used. No statistically significant 253
difference was found between the two groups. 254
QEEG data of AD patients with and without 255
epilepsy are shown in Table 4. AD-EPI group showed 256
higher relative power values in the sigma band com- 257
pared with the AD-CTR group, which however did 258
not survive to Bonferroni’s correction for multiple 259
comparisons. 260
DISCUSSION 261
In the present study, we evaluated a large cohort 262
of consecutive outpatients admitted to our univer- 263
sity memory clinic from 1999 to 2016. We selected 264
patients who received a diagnosis of neurodegener- 265
ative dementia and who also were suffering from 266
epilepsy. We exclude patients who had a remote 267
onset of epilepsy, in order to investigate the possi- 268
ble relationship between the onset of epilepsy and 269
the neurodegenerative process underlying dementia. 270
The first result is that the prevalence of epilepsy 271
was similar for AD, bvFTD, and DLB dementias. 272
Instead, PPA patients showed higher prevalence of 273
epilepsy. However, this result must be interpreted 274
with caution, considering the limited number of PPA 275
Table 1
Characteristics of epileptic seizures in patients affected by neurodegenerative dementias. For age,
mean values ± standard deviation are shown
Total AD bvFTD DLB PPA
38 30 3 2 3
Age 72.7 ± 7.7 71.9 ± 8.0 71.3 ± 5.5 67.0 ± 7.1 67.3 ± 4.5
Epilepsy Onset
-After Dementia diagnosis 21 (55.3%) 15 1 2 3
-Before Dementia diagnosis 7 (18.4%) 5 2 0 0
-Concomitant with Dementia diagnosis 7 (18.4%) 7 0 0 0
-Unknown 3 (7.9%) 3 0 0 0
Seizures type at onset
-Generalized 17 (44.7%) 15 1 1 0
-Focal 15 (39.5%) 10 1 1 3
-Unknown 6 (15.79%) 5 1 0 0
Treatment Response
-Seizure Free 24 (63.2%) 23 0 0 1
-Improved 3 (7.9%) 0 2 1 0
-Not Improved 11 (28.9%) 7 1 1 2
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; bvFTD, frontotemporal dementia, behavioral variant;
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Table 2
Main clinical and demographic data in subjects with dementia due to AD and epilepsy (AD-EPI)
and subjects with dementia due to AD without epilepsy (AD-CTR). Mean values ± standard
deviation (range) are shown
AD-EPI AD-CTR p
N 22 22
Age, y 71.95 ± 8.00 (57–90) 72.27 ± 6.85 (54–82) n.s.
Gender 26F/4M 17F/5M n.s.
Education, y 7.41 ± 4.06 (0–17) 9.45 ± 4.60 (2–17) n.s.
MMSE 24.14 ± 4.36 (10–30) 23.95 ± 3.64 (15–30) n.s.
GDS 5.05 ± 3.22 (0–12) 5.14 ± 3.09 (2–15) n.s.
AChE-inhibitors 11 (50%) 4 (23%) n.s.
Hypertension 16 (73%) 10 (46%) n.s.
Diabetes 3 (14%) 2 (9%) n.s.
Heart disease 6 (27%) 7 (32%) n.s.
Hypercholesterolemia 12 (54%) 11 (50%) n.s.
Follow-up, mo 54.0 ± 34.0 (8–118) 50.8 ± 30.7 (5–124) n.s.
Follow-up MMSE 13.8 ± 7.7 (4–30) 11.4 ± 8.27 (1–28) n.s.
AChE-inhibitors, acetylcholinesterase inhibitors; F, female; GDS, Geriatric depression scale; M, male;
MMSE, Mini-Mental State Examination; n.s., not significant.
Table 3
Neuropsychological tests raw scores in subjects with dementia due to Alzheimer’s disease and
epilepsy (AD-EPI) and subjects with dementia due to Alzheimer’s disease without epilepsy
(AD-CTR). Mean values ± standard deviation (range) are shown
AD-EPI AD-CTR p
TMT A (s) 125.94 ± 95.37 (29–350) 112.63 ± 71.95 (41–300) n.s.
TMT B (s) 362.44 ± 171.54 (88–533) 343 ± 180.51 (89–533) n.s.
Symbol-digit 16.00 ± 11.87 (1–42) 16.50 ± 9.55 (1–34) n.s.
Stroop Color 29.06 ± 6.52 (18–45) 28.94 ± 8.74 (9–43) n.s.
Stroop Color-word 10.74 ± 6.06 (1–21) 8.13 ± 4.90 (3–17) n.s.
Corsi’s Span 3.29 ± 1.36 (0–5) 3.73 ± 1.22 (2–6) n.s.
Digit’s Span 5.76 ± 2.56 (3–15) 4.87 ± 0.64 (4–6) n.s.
RALVT immediate 23.35 ± 9.96 (6–49) 19.89 ± 6.91 (11–34) n.s.
RALVT delayed 2.40 ± 2.68 (0–7) 2.16 ± 2.57 (0–9) n.s.
CDT 3.83 ± 3.15 (0–7) 4.41 ± 3.02 (0–7) n.s.
Figure copying, simple copy 6.95 ± 2.22 (2–10) 7.57 ± 2.31 (3–12) n.s.
Figure copying, with guiding landmarks 56.21 ± 12.58 (24–68) 59.05 ± 9.75 (38–70) n.s.
Categorical verbal fluency 13.01 ± 5.03 (2–23) 12.93 ± 3.83 (8–21) n.s.
Phonological verbal fluency 24.30 ± 9.81 (0–39) 20.14 ± 9.65 (10–49) n.s.
CDT, Clock drawing test; n.s., not significant; RALVT, Rey Auditory Learning Verbal Test; TMT, Trail
Making Test.
subjects in our sample, which is notoriously rare276
[19]. The second result is the statistically significant277
association between the response to AED and the278
diagnosis of neurodegenerative dementia. In partic-279
ular, among the various type of dementias, patients280
with AD showed a better response to AED therapy.281
However, it has to be noted that the other groups were282
smaller than the AD group, thus this result also must283
be taken with caution.284
AD is the most common neurodegenerative285
dementia [32]. Growing literature data are suggest-286
ing the association between brain amyloidosis and287
epilepsy [8, 33]. Indeed, seizures can also precede288
cognitive symptoms in AD patients [34]. In agree-289
ment with literature data, in our cohort AD is the290
most common cause of degenerative dementia and 291
it is also the most common cause of dementia in 292
the group of patients with neurodegenerative demen- 293
tias and concomitant epilepsy. However, in our study 294
the prevalence of epilepsy of other common neu- 295
rodegenerative dementias (FTD and DLB) is at least 296
comparable with AD. 297
Few studies have investigated epilepsy in non-AD 298
neurodegenerative dementias. A recent epidemio- 299
logical study in the United States showed that AD 300
dementia had a higher risk of developing seizures 301
and epilepsy compared with non-AD dementias [9]. 302
However, in that study all non-AD dementias were 303
considered, including vascular and other secondary 304













6 D. Arnaldi et al. / Epilepsy in Neurodegenerative Dementias
Table 4
qEEG data in subjects with dementia due to AD and epilepsy (AD-
EPI) and subjects with dementia due to AD without epilepsy (AD-




-Frontal 7.73 ± 3.16 7.59 ± 3.84 n.s.
-Temporal 8.81 ± 4.10 7.59 ± 2.89 n.s.
-Centro/Parietal 7.72 ± 3.29 7.30 ± 3.32 n.s.
-Occipital 6.50 ± 3.05 6.87 ± 3.61 n.s.
THETA (4.10–8 Hz)
-Frontal 18.93 ± 8.66 18.35 ± 9.66 n.s.
-Temporal 20.92 ± 9.65 19.90 ± 9.89 n.s.
-Centro/Parietal 19.77 ± 8.99 19.31 ± 9.35 n.s.
-Occipital 17.48 ± 8.27 19.20 ± 10.04 n.s.
ALPHA (8.10–12 Hz)
-Frontal 20.17 ± 11.72 17.55 ± 9.14 n.s.
-Temporal 20.73 ± 9.08 18.95 ± 8.39 n.s.
-Centro/Parietal 25.82 ± 12.28 24.59 ± 11.57 n.s.
-Occipital 32.39 ± 19.88 28.73 ± 15.00 n.s.
SIGMA (12.10–16 Hz)
-Frontal 6.29 ± 2.70 4.69 ± 2.57 0.033∗
-Temporal 6.61 ± 2.23 5.21 ± 2.34 0.034∗
-Centro/Parietal 8.97 ± 3.78 6.72 ± 2.99 0.023∗
-Occipital 6.88 ± 2.66 5.73 ± 2.73 n.s.
BETA (16.10–24 Hz)
-Frontal 8.03 ± 2.90 7.59 ± 5.04 n.s.
-Temporal 7.23 ± 2.57 6.89 ± 3.21 n.s.
-Centro/Parietal 9.59 ± 3.58 8.59 ± 4.25 n.s.
-Occipital 6.49 ± 2.87 6.42 ± 3.21 n.s.
Mean frequency
-Frontal 11.14 ± 1.44 10.82 ± 1.66 n.s.
-Temporal 10.96 ± 1.22 10.74 ± 1.19 n.s.
-Centro/Parietal 9.72 ± 1.05 9.45 ± 1.02 n.s.
-Occipital 10.68 ± 1.41 10.62 ± 1.14 n.s.
∗Not surviving Bonferroni’s correction for multiple comparison.
administrative database, thus it was unknown whether306
the epilepsy was of new or remote onset. Another307
recent study was aimed at evaluating the relative308
incidence of seizures in neurodegenerative demen-309
tias [35] showing that the cumulative probability of310
developing seizures after dementia onset was higher311
in AD and DLB compared with FTD. It has to be312
noted that FTD patients have shorter life expectancy313
than non-FTD dementias and this may contribute to314
their lower cumulative probability of seizures. How-315
ever, that study was aimed at identifying the incidence316
of seizures, but it is not known whether the patients317
further develop epilepsy that needed antiepileptic318
treatment. According to international criteria, a single319
seizure is not enough to make epilepsy diagno-320
sis [36], unless a chronic predisposing factor for321
developing successive seizures may be demonstrated.322
Indeed, several causes of provoked seizures has been323
described, especially in the elderly [37]. In the present324
study, we selected only those patients who were diag-325
nosed as having epilepsy, with causes of provoked 326
seizures being excluded, and therefore underwent 327
antiepileptic treatment. This is because we believe 328
that this approach would increase the probability 329
that the pathophysiology of seizures in the evalu- 330
ated patients is directly related to the pathophysiology 331
of neurodegenerative dementias. With this specific 332
study design, we found that the prevalence of def- 333
inite epilepsy that requested antiepileptic treatment 334
is similar for AD and non-AD neurodegenerative 335
dementias and it is lower range with respect to the 336
reported prevalence of seizures in literature studies, 337
which ranges from 0.5 to 64% [38]. However, the 338
largest epidemiological study conducted so far on 339
more than 3 million AD patients found a seizure 340
prevalence of 1.43% [9], thus very close to the preva- 341
lence in the present study. Moreover, the weighted 342
average prevalence of epilepsy in AD, according to 343
literature data [38], is 1.5%. A recent study [39] 344
found an epilepsy prevalence of 25.7% in a cohort 345
of patients with dementia or mild cognitive impair- 346
ment. However, this study has several methodological 347
discrepancies in comparison with our, including the 348
presence of vascular dementia and the inclusion of 349
patients with clinical suspect of epilepsy, but with- 350
out anti-epileptic treatment. If the same criteria used 351
in our study are applied to Baker et al dataset, the 352
epilepsy prevalence would decrease to 2.1 %, thus 353
comparable to our result. 354
The underlying mechanism of epileptogenesis in 355
neurodegenerative dementias is thought to be related 356
to an increased cortical excitability due to corti- 357
cal deposition/aggregation of pathological proteins. 358
In AD, network hyperexcitability has been related 359
to aberrant network activity due to amyloid- [33]. 360
However, both increased seizure susceptibility and 361
aberrant network excitability have been related to the 362
overexpression of both tau protein and -synuclein 363
in animal models of FTD [40] and DLB [41]. Thus, 364
the precise cause of epileptic seizures in patients with 365
neurodegenerative dementias has not been fully elu- 366
cidated yet, and it is likely underlined by complex 367
mechanism and heterogeneous neuropathology. For 368
instance, it has been proposed that both amyloid- 369
 and tau protein abnormalities must be present to 370
produce aberrant excitatory activity that results in 371
epileptic seizures [42]. Moreover, in non-demented 372
patients suffering from refractory temporal lobe 373
epilepsy, the presence of tau pathology has been 374
related cognitive decline [43]. Thus, the role of tau 375
protein seems relevant in determining the increased 376
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in AD, but it may also be present in FTD and DLB378
[44]. The results of the present study seem to sug-379
gest a preponderant role of tau protein among all380
misfolded ones. Indeed, combining PDD and DLB,381
where -synuclein is invariable and amyloid- very382
common, the frequency of epilepsy is extremely low383
(approximately 0.7%), while the highest frequency384
has been observed in PPA, of which the non-fluent385
type is mainly related to tau deposition. This is in386
agreement with recent literature data highlighting the387
role of tau protein in increasing seizure susceptibility388
and aberrant network excitability [4, 44].389
A novel finding of the present study is that epilepsy390
in AD dementia seems to be more drug-responsive391
than epilepsy in non-AD dementias. As discussed392
before, this result must be taken with caution consid-393
ering the limited number of subjects. Nevertheless,394
considering that AD is the most frequent cause of395
neurodegenerative dementia, we performed a sec-396
ond analysis aimed at evaluating whether patients397
with AD and epilepsy (AD-EPI) had different clin-398
ical, neuropsychological and EEG characteristics399
compared with patients with AD without epilepsy400
(AD-CTR). The two groups were matched for age,401
education, and MMSE score in order to evaluate the402
real effect of epilepsy on such patients. No signif-403
icant differences were found in neuropsychological404
and qEEG data between the two groups. AD-EPI405
patients tended to have higher values of relative406
power in the sigma band (12.10–16 Hz) in several407
brain regions, without surviving Bonferroni’s cor-408
rection for multiple comparison. This finding could409
have different interpretations. The first hypothesis410
is that the increase in the sigma band may be an411
expression of an increased neuronal excitability due412
to epileptic pathology in AD-EPI subjects. The sta-413
tistical significance may not be achieved because of414
the relatively limited number of subjects. The second,415
more likely, hypothesis is that the increase of rapid416
EEG frequencies is due to the chronic effect of AED417
therapy.418
Several literature data showed the effect of AED419
on qEEG data. For example, “old generation” AEDs420
(such as phenytoin, carbamazepine and phenobar-421
bital) tend to increase the relative power of slow422
bands [45–47]. On the other hand, “new generation”423
AEDs (such as levetiracetam and lamotrigine) tend424
to increase the relative power of the fast bands [48,425
49]. Unfortunately, in our study, considering the lim-426
ited number of subjects, it was not possible to make427
a more detailed analysis of this phenomenon. How-428
ever, in the AD-EPI group, about half (12/25) of the429
subjects took levetiracetam while the remainder took 430
“old generation” AEDs. 431
The qEEG can be considered an indirect marker 432
of neurodegeneration in AD [50]. In our study, the 433
qEEG data were found to be substantially overlapping 434
between AD-EPI and AD-CTR patients while, as a 435
descriptive finding, interictal epileptiform discharges 436
were more likely found in the AD-EPI group. Further- 437
more, the two study groups did not show statistically 438
significant difference in cognitive test performance. 439
Therefore, although previous studies have reported an 440
association between epilepsy and amyloidosis in AD 441
[8, 33], in the present study subjects with concomitant 442
AD and epilepsy did not have a mo e severe clinical 443
phenotype or a more sever neurodegeneration, mea- 444
sured indirectly with the EEG. Indeed, clinical studies 445
have reported only a moderate correlation between 446
cerebral amyloidosis markers and neurodegeneration 447
markers in AD [51–53]. The clinical significate of this 448
result remains to be investigated through the study of 449
amyloidosis and neurodegeneration markers. 450
As a descriptive finding, the presence of seizures 451
was perceived as a major clinical problem by patients 452
and caregivers, especially those with seizures with 453
motor component. Besides that, no clinically relevant 454
association with concomitant medications, comor- 455
bidities or rate of worsening during the clinical 456
follow-up was found. In particular, AD-EPI did not 457
have a worse cognitive outcome compared with AD- 458
CTR patients, thus suggesting that the presence of 459
epilepsy does not significantly interfere with the clin- 460
ical course of the disease. 461
The present study has some limitations. The first 462
is that the data were collected retrospectively. How- 463
ever, the data were collected homogeneously over the 464
years by the same researchers and with standardized 465
diagnostic procedures. Nevertheless, the retrospec- 466
tive nature of the study may have led to a slight 467
underestimation of the epilepsy prevalence in our 468
study. The second limit is the lack of biomarkers for 469
brain amyloidosis and tau protein. Unfortunately, for 470
most patients this marker was not available in our cen- 471
ter yet, considering that the study period is from 1999 472
to 2016. Third, non-AD dementias were less repre- 473
sented than AD in our sample, thus larger studies are 474
needed to draw definite conclusions. 475
In conclusion, we have found that in our cohort 476
of neurodegenerative dementia, AD, FTD, and DLB 477
dementias have similar prevalence of epilepsy, even 478
if AD patients were more responsive to antiepileptic 479
treatment. Moreover, AD patients with epilepsy did 480
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qEEG differences compared with AD patients with-482
out epilepsy. Larger studies are needed to confirm483
these findings.484
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